MX2010007672A - Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion. - Google Patents

Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.

Info

Publication number
MX2010007672A
MX2010007672A MX2010007672A MX2010007672A MX2010007672A MX 2010007672 A MX2010007672 A MX 2010007672A MX 2010007672 A MX2010007672 A MX 2010007672A MX 2010007672 A MX2010007672 A MX 2010007672A MX 2010007672 A MX2010007672 A MX 2010007672A
Authority
MX
Mexico
Prior art keywords
preparing
bupropion hydrochloride
sustained release
same
release composition
Prior art date
Application number
MX2010007672A
Other languages
English (en)
Inventor
Gour Mukherji
Anuj Kumar Fanda
Maulik Kiritkumar Panchal
Original Assignee
Jubilant Organosys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Organosys Ltd filed Critical Jubilant Organosys Ltd
Publication of MX2010007672A publication Critical patent/MX2010007672A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describe una composición farmacéutica estabilizada de liberación sostenida de clorhidrato de bupropión y el proceso para la preparación de la misma, en donde la composición farmacéutica comprende una cantidad terapéuticamente eficaz de clorhidrato de bupropión fino sin recubrimiento y adyuvantes farmacéuticamente aceptables, y en donde la composición no contiene un estabilizante ácido y contiene menos de aproximadamente 0.3% en peso de ácido m-clorobenzoico.
MX2010007672A 2008-01-14 2008-11-19 Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion. MX2010007672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN117DE2008 2008-01-14
PCT/IN2008/000777 WO2009090670A2 (en) 2008-01-14 2008-11-19 Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same

Publications (1)

Publication Number Publication Date
MX2010007672A true MX2010007672A (es) 2010-10-07

Family

ID=54291754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007672A MX2010007672A (es) 2008-01-14 2008-11-19 Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.

Country Status (10)

Country Link
US (1) US20100291225A1 (es)
EP (1) EP2229053A4 (es)
KR (1) KR20100107044A (es)
AU (1) AU2008347949A1 (es)
BR (1) BRPI0819957A2 (es)
CA (1) CA2713365A1 (es)
MX (1) MX2010007672A (es)
RU (1) RU2010133982A (es)
WO (1) WO2009090670A2 (es)
ZA (1) ZA201004830B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9675585B1 (en) * 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
KR102536511B1 (ko) * 2020-06-25 2023-05-26 (주) 넥스팜코리아 날트렉손 서방형 매트릭스 제제와 부프로피온 서방형 매트릭스 제제의 단층정 복합제제와 그 제조 방법
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
US20240000729A1 (en) * 2022-06-30 2024-01-04 Axsome Therapeutics, Inc. Microparticles containing bupropion
WO2024006853A1 (en) 2022-06-30 2024-01-04 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
PL196544B1 (pl) * 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
EP1703907A4 (en) * 2003-12-29 2009-03-25 Jason Mcdevitt COMPOSITIONS AND METHODS FOR TREATING RECURRENT CONDITIONS
US20060204571A1 (en) * 2005-03-12 2006-09-14 Sun Pharmaceutical Industries Limited Stable compositions of bupropion or its pharmaceutically acceptable salts
EP1896002A4 (en) * 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
WO2008023390A2 (en) * 2006-08-21 2008-02-28 Jubilant Organosys Limited Modified release pharmaceutical composition of bupropion hydrochloride
WO2010004386A2 (en) * 2008-06-16 2010-01-14 Glenmark Generics Limited Amorphous bupropion hydrobromide and preparation thereof

Also Published As

Publication number Publication date
CA2713365A1 (en) 2009-07-23
US20100291225A1 (en) 2010-11-18
AU2008347949A1 (en) 2009-07-23
EP2229053A4 (en) 2011-01-12
KR20100107044A (ko) 2010-10-04
ZA201004830B (en) 2011-03-30
RU2010133982A (ru) 2012-02-27
WO2009090670A3 (en) 2009-12-30
EP2229053A2 (en) 2010-09-22
WO2009090670A2 (en) 2009-07-23
WO2009090670A8 (en) 2009-09-11
BRPI0819957A2 (pt) 2015-09-15

Similar Documents

Publication Publication Date Title
MX2010007672A (es) Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
MX2010003923A (es) Formulacion farmaceutica de valsartan.
UA105229C2 (uk) Фармацевтичний склад
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010053861A3 (en) Biologically active amides
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
MX2007014963A (es) Composicion de liberacion modificada de al menos una forma de venlafaxina.
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2011091225A3 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
WO2011132901A3 (en) Novel benzamide derivatives
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal